Skip to main content

Advertisement

SpringerLink
Log in

Long-term clinical effect of Tangyiping Granules (糖异平颗粒) on patients with impaired glucose tolerance

  • Original Article
  • Published:
Chinese Journal of Integrative Medicine Aims and scope Submit manuscript

Abstract

Objective

To evaluate the long-term clinical effect of Tangyiping Granules (糖异平颗粒, TYP) on patients with impaired glucose tolerance (IGT) to achieve normal glucose tolerance (NGT) and hence preventing them from conversion to diabetes mellitus (DM).

Methods

In total, 127 participants with IGT were randomly assigned to the control (63 cases, 3 lost to follow-up) and treatment groups (64 cases, 4 lost to follow-up) according to the random number table. The control group received lifestyle intervention alone, while the patients in the treatment group took orally 10 g of TYP twice daily in addition to lifestyle intervention for 12 weeks. The rates of patients achieving NGT or experiencing conversion to DM as main outcome measure were observed at 3, 12, and 24 months after TYP treatment. The secondary outcome measures included fasting plasma glucose (FPG), 2-h postprandial plasma glucose (2hPG), glycosylated hemoglobin (HbA1c), fasting insulin (FINS), 2-h insulin (2hINS), homeostatic model assessment of insulin resistance (HOMA-IR), blood lipid and patients' complains of Chinese medicine (CM) symptoms before and after treatment.

Results

A higher proportion of the treatment group achieved NGT compared with the control group after 3-, 12- and 24-month follow-up (75.00% vs. 43.33%, 58.33% vs. 35.00%, 46.67% vs. 26.67%, respectively, P<0.05). The IGT to DM conversion rate of the treatment group was significantly lower than that of the control group at the end of 24-month follow-up (16.67% vs. 31.67%, P<0.05). Before treatment, FPG, 2hPG, HbA1c, FINS, 2hINS, HOMA-IR, triglyceride (TG), total cholesterol, low- and high-density lipoprotein cholesterol levels had no statistical difference between the two groups (P>0.05). After treatment, the 2hPG, HbA1c, HOMA-IR, and TG levels of the treatment group decreased significantly compared with those of the control group (P<0.05). CM symptoms such as exhaustion, irritability, chest tightness and breathless, spontaneous sweating, constipation, and dark thick and greasy tongue were significantly improved in the treatment group as compared with the control group (P<0.05). No severe adverse events occurred.

Conclusion

TYP administered at the IGT stage with a disciplined lifestyle delayed IGT developing into type 2 DM.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2012;35(Suppl 1):S64–S71.

    Article  Google Scholar 

  2. Xu Y, Wang L, He J, Bi Y, Li M, Wang T, et al. Prevalence and control of diabetes in Chinese adults. JAMA 2013;310:948–959.

    Article  CAS  PubMed  Google Scholar 

  3. Xiang HD, Wu W, Liu CQ, Li K, Feng JG, Zhang YT, et al. The 1996 national diabetes epidemiological features of the baseline survey report. Chin Diabetes (Chin) 1998;6:131–133.

    Google Scholar 

  4. Mainous AG 3rd, Tanner RJ, Baker R, Zayas CE, Harle CA. Prevalence of prediabetes in England from 2003 to 2011: population-based, cross-sectional study. BMJ Open 2014;4:e005002.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Rosettenstein K, Viecelli A, Yong K, Nguyen HD, Chakera A, Chan D, et al. Diagnostic accuracies of glycated hemoglobin, fructosamine, and homeostasis model assessment of insulin resistance in predicting impaired fasting glucose, impaired glucose tolerance, or new onset diabetes after transplantation. Transplantation 2015: 292:657–658.

    Google Scholar 

  6. Perreault L, Pan Q, Mather KJ, Watson KE, Hamman RF, Kahn SE. Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study. Lancet 2012;379:2243–2251.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J, et al. Prevalence of diabetes among men and women in China. New Engl J Med 2010;362:1090–1101.

    Article  CAS  PubMed  Google Scholar 

  8. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997;20:537–544.

    Article  CAS  Google Scholar 

  9. Schellenberg ES, Dryden DM, Vandermeer B, Ha C, Korownyk C. Lifestyle interventions for patients with and at risk for type 2 diabetes: a systematic review and metaanalysis. Ann Intern Med 2013;159:543–551.

    Article  PubMed  Google Scholar 

  10. Kanaya AM, Narayan KM. Prevention of type 2 diabetes: data from recent trials. Prim Care 2003;30:511–526.

    Article  CAS  PubMed  Google Scholar 

  11. Laakso M. Prevention of type 2 diabetes. Curr Molecul Med 2005;5:365–374.

    Article  CAS  Google Scholar 

  12. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New Engl J Med 2002;346:393–403.

    Article  CAS  PubMed  Google Scholar 

  13. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002;359:2072–2077.

    Article  CAS  PubMed  Google Scholar 

  14. Yin J, Zhang H, Ye J. Traditional Chinese medicine in treatment of metabolic syndrome. Endocr Metab Immun Disord Drug Targets 2008;8:99–111.

    Article  CAS  Google Scholar 

  15. Xu YS, Huang YQ. Clinical observation of Tangyiping Water Pills in treatment of patients with impaired glucose tolerance and the effect on glucolipid metabolism and inflammatory factors. Chin J Inf Tradit Chin Med (Chin) 2012;19:13–15.

    CAS  Google Scholar 

  16. Trumbo P, Schlincker S, Yates AA, Poos M, Food and Nutrition Board of the Institute of Medicine, The National Academies. Dietary reference intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein, and amino acids. J Am Diet Assoc 2002;102:1621–1630.

    Article  PubMed  Google Scholar 

  17. Zheng XY, ed. Guiding principle of clinical research on new Chinese medicine drugs. Beijing: China Medical Science and Technology Press;2002:233–237.

  18. Ishikawa S, Shimano M, Watarai M, Koyasu M, Uchikawa T, Ishii H, et al. Impact of sitagliptin on carotid intima-media thickness in patients with coronary artery disease and impaired glucose tolerance or mild diabetes mellitus. Am J Cardiol 2014;114:384–388.

    Article  CAS  PubMed  Google Scholar 

  19. Ring M, Eriksson MJ, Fritz T, Nyberg G, Östenson CG, Krook A, et al. Influence of physical activity and gender on arterial function in type 2 diabetes, normal and impaired glucose tolerance. Diab Vasc Dis Res 2015;12:315–324.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Zhao Y, Li X, Tang S. Retrospective analysis of the relationship between elevated plasma levels of TXNIP and carotid intima-media thickness in subjects with impaired glucose tolerance and early type 2 diabetes mellitus. Diabetes Res Clin Pract 2015;109:372–377.

    Article  CAS  PubMed  Google Scholar 

  21. Sinnott M, Kinsley BT, Jackson AD, Walsh C, O'Grady T, Nolan JJ, et al. Fasting plasma glucose as initial screening for diabetes and prediabetes in irish adults: The Diabetes Mellitus and Vascular Health Initiative (DMVhi). PLoS One 2015;15;10:e0122704.

    Article  Google Scholar 

  22. Li G, Zhang P, Wang J, Gregg EW, Yang W, Gong Q, et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet 2008;371:1783–1789.

    Article  PubMed  Google Scholar 

  23. Liu C. TRIPOD Research Introduction and review of Liaoning. J Pract Diabetol (Chin) 2004;12:7–9.

    Google Scholar 

  24. Fang J, Wei H, Sun Y, Zhang X, Liu W, Chang Q, et al. Regulation of podocalyxin expression in the kidney of streptozotocin-induced diabetic rats with Chinese herbs (Yishen Capsule). BMC Complement Alternat Med 2013;13:280–282.

    Article  Google Scholar 

  25. Fang Z, Zhao J, Shi G, Shu Y, Ni Y, Wang H, et al. Shenzhu Tiaopi Granule combined with lifestyle intervention therapy for impaired glucose tolerance: a randomized controlled trial. Complement Therap Med 2014;22:842–850.

    Article  Google Scholar 

  26. Liu M, Qin J, Hao Y, Liu M, Luo J, Luo T, et al. Astragalus polysaccharide suppresses skeletal muscle myostatin expression in diabetes: involvement of ROSERK and NF-kappaB pathways. Oxid Med Cell Longev 2013;2013:782497.

    PubMed  PubMed Central  Google Scholar 

  27. Jiang S, Wang Y, Ren D, Li J, Yuan G, An L, et al. Antidiabetic mechanism of Coptis chinensis polysaccharide through its antioxidant property involving the JNK pathway. Pharm Biol 2015;53:1022–1029.

    Article  CAS  PubMed  Google Scholar 

  28. Kianbakht S, Dabaghian FH. Improved glycemic control and lipid profile in hyperlipidemic type 2 diabetic patients consuming Salvia officinalis L. leaf extract: a randomized placebo controlled clinical trial. Complement Ther Med 2013;21:441–446.

    Article  CAS  PubMed  Google Scholar 

  29. She S, Liu W, Li T, Hong Y. Effects of puerarin in STZinduced diabetic rats by oxidative stress and the TGFbeta1/Smad2 pathway. Food Funct 2014;5:944–950.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Endocrinology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, 250014, China

    Yan-qin Huang  (黄延芹), Qing-feng Yang  (杨清峰), Hua Wang  (王 华), Wei Peng  (彭 伟) & Yue-hua Jiang  (姜月华)

  2. Department of Endocrinology, The Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, 250001, China

    Yun-sheng Xu  (徐云生)

Authors
  1. Yan-qin Huang  (黄延芹)
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Qing-feng Yang  (杨清峰)
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hua Wang  (王 华)
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yun-sheng Xu  (徐云生)
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Wei Peng  (彭 伟)
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yue-hua Jiang  (姜月华)
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yun-sheng Xu  (徐云生).

Additional information

Supported by Shandong Province Science and Technology Program for Public Wellbing (No. 2014kjhm0106) and Shandong Province Science and Technology Development Plan (No. 2006GG3202011), China

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Huang, Yq., Yang, Qf., Wang, H. et al. Long-term clinical effect of Tangyiping Granules (糖异平颗粒) on patients with impaired glucose tolerance. Chin. J. Integr. Med. 22, 653–659 (2016). https://doi.org/10.1007/s11655-016-2512-3

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11655-016-2512-3

Keywords

Search

Navigation